RECALLS AND SAFETY ALERTS SERIOUS FUNGAL INFECTIONS WITH SIMPONI
August 10, 2009
FDA is reminding healthcare professionals about the risk of serious fungal infections with TNF blockers, including Simponi (golimumab), which was recently approved. TNF blockers are immunosuppressants used to treat chronic inflammatory diseases, incl...
Full Story Below
Rapid Response
Free Case Evaluation
The Help You Need,
When You Need it Most
More from FDA News Directory
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
